Differences  ||| S:0 E:12 ||| NNS
in  ||| S:12 E:15 ||| IN
pathophysiology  ||| S:15 E:31 ||| NN
between  ||| S:31 E:39 ||| IN
rheumatoid  ||| S:39 E:50 ||| JJ
arthritis  ||| S:50 E:60 ||| NN
and  ||| S:60 E:64 ||| CC
ankylosing  ||| S:64 E:75 ||| FW
spondylitis  ||| S:75 E:87 ||| FW
Rheumatoid  ||| S:87 E:98 ||| FW
arthritis  ||| S:98 E:108 ||| FW
and  ||| S:108 E:112 ||| CC
ankylosing  ||| S:112 E:123 ||| JJ
spondylitis  ||| S:123 E:135 ||| NNS
are  ||| S:135 E:139 ||| VBP
common  ||| S:139 E:146 ||| JJ
and  ||| S:146 E:150 ||| CC
severe  ||| S:150 E:157 ||| JJ
chronic  ||| S:157 E:165 ||| JJ
inflammatory  ||| S:165 E:178 ||| JJ
skeletal  ||| S:178 E:187 ||| JJ
diseases ||| S:187 E:195 ||| NNS
.  ||| S:195 E:197 ||| .
Recognizing  ||| S:197 E:209 ||| VBG
the  ||| S:209 E:213 ||| DT
differences  ||| S:213 E:225 ||| NNS
rather  ||| S:225 E:232 ||| RB
than  ||| S:232 E:237 ||| IN
emphasizing  ||| S:237 E:249 ||| VBG
similarities  ||| S:249 E:262 ||| NN
is  ||| S:262 E:265 ||| VBZ
important  ||| S:265 E:275 ||| JJ
for  ||| S:275 E:279 ||| IN
a  ||| S:279 E:281 ||| DT
better  ||| S:281 E:288 ||| JJR
understanding  ||| S:288 E:302 ||| NN
of  ||| S:302 E:305 ||| IN
the  ||| S:305 E:309 ||| DT
disease  ||| S:309 E:317 ||| NN
processes ||| S:317 E:326 ||| NNS
,  ||| S:326 E:328 ||| ,
the  ||| S:328 E:332 ||| DT
identification  ||| S:332 E:347 ||| NN
of  ||| S:347 E:350 ||| IN
specific  ||| S:350 E:359 ||| JJ
therapeutic  ||| S:359 E:371 ||| JJ
targets  ||| S:371 E:379 ||| NNS
and  ||| S:379 E:383 ||| CC
in  ||| S:383 E:386 ||| IN
the  ||| S:386 E:390 ||| DT
long-term  ||| S:390 E:400 ||| JJ
better  ||| S:400 E:407 ||| JJR
treatment  ||| S:407 E:417 ||| NN
options  ||| S:417 E:425 ||| NNS
for  ||| S:425 E:429 ||| IN
the  ||| S:429 E:433 ||| DT
individual  ||| S:433 E:444 ||| JJ
patients ||| S:444 E:452 ||| NNS
.  ||| S:452 E:454 ||| .
We  ||| S:454 E:457 ||| PRP
discuss  ||| S:457 E:465 ||| VB
a  ||| S:465 E:467 ||| DT
number  ||| S:467 E:474 ||| NN
of  ||| S:474 E:477 ||| IN
pathophysiological  ||| S:477 E:496 ||| JJ
differences  ||| S:496 E:508 ||| NNS
between  ||| S:508 E:516 ||| IN
rheumatoid  ||| S:516 E:527 ||| JJ
arthritis  ||| S:527 E:537 ||| NN
and  ||| S:537 E:541 ||| CC
ankylosing  ||| S:541 E:552 ||| JJ
spondylitis  ||| S:552 E:564 ||| NN
by  ||| S:564 E:567 ||| IN
looking  ||| S:567 E:575 ||| VBG
at  ||| S:575 E:578 ||| IN
the  ||| S:578 E:582 ||| DT
anatomical  ||| S:582 E:593 ||| JJ
characteristics ||| S:593 E:608 ||| NNS
,  ||| S:608 E:610 ||| ,
differences  ||| S:610 E:622 ||| NNS
and  ||| S:622 E:626 ||| CC
similarities  ||| S:626 E:639 ||| NNS
in  ||| S:639 E:642 ||| IN
the  ||| S:642 E:646 ||| DT
autoimmune  ||| S:646 E:657 ||| NN
and  ||| S:657 E:661 ||| CC
autoinflammatory  ||| S:661 E:678 ||| JJ
reactions ||| S:678 E:687 ||| NNS
,  ||| S:687 E:689 ||| ,
association  ||| S:689 E:701 ||| NN
with  ||| S:701 E:706 ||| IN
other  ||| S:706 E:712 ||| JJ
immune  ||| S:712 E:719 ||| JJ
mediated  ||| S:719 E:728 ||| JJ
inflammatory  ||| S:728 E:741 ||| JJ
diseases ||| S:741 E:749 ||| NNS
,  ||| S:749 E:751 ||| ,
structural  ||| S:751 E:762 ||| JJ
outcome ||| S:762 E:769 ||| NN
,  ||| S:769 E:771 ||| ,
and  ||| S:771 E:775 ||| CC
their  ||| S:775 E:781 ||| PRP$
potential  ||| S:781 E:791 ||| JJ
significance  ||| S:791 E:804 ||| NN
for  ||| S:804 E:808 ||| IN
further  ||| S:808 E:816 ||| JJ
therapeutic  ||| S:816 E:828 ||| JJ
developments ||| S:828 E:840 ||| NNS
.  ||| S:840 E:842 ||| .
Further  ||| S:842 E:850 ||| JJ
research  ||| S:850 E:859 ||| NN
into  ||| S:859 E:864 ||| IN
the  ||| S:864 E:868 ||| DT
differences  ||| S:868 E:880 ||| NNS
between  ||| S:880 E:888 ||| IN
these  ||| S:888 E:894 ||| DT
diseases  ||| S:894 E:903 ||| NNS
should  ||| S:903 E:910 ||| MD
focus  ||| S:910 E:916 ||| VB
on  ||| S:916 E:919 ||| IN
the  ||| S:919 E:923 ||| DT
specific  ||| S:923 E:932 ||| JJ
nature  ||| S:932 E:939 ||| NN
of  ||| S:939 E:942 ||| IN
the  ||| S:942 E:946 ||| DT
immune ||| S:946 E:952 ||| JJ
/ ||| S:952 E:953 ||| CD
inflammatory  ||| S:953 E:966 ||| JJ
components ||| S:966 E:976 ||| NNS
,  ||| S:976 E:978 ||| ,
the  ||| S:978 E:982 ||| DT
role  ||| S:982 E:987 ||| NN
of  ||| S:987 E:990 ||| IN
resident  ||| S:990 E:999 ||| JJ
cells  ||| S:999 E:1005 ||| NNS
in  ||| S:1005 E:1008 ||| IN
the  ||| S:1008 E:1012 ||| DT
joint  ||| S:1012 E:1018 ||| JJ
and  ||| S:1018 E:1022 ||| CC
joint-associated  ||| S:1022 E:1039 ||| JJ
tissues ||| S:1039 E:1046 ||| NNS
,  ||| S:1046 E:1048 ||| ,
the  ||| S:1048 E:1052 ||| DT
types  ||| S:1052 E:1058 ||| NNS
and  ||| S:1058 E:1062 ||| CC
mechanisms  ||| S:1062 E:1073 ||| NNS
of  ||| S:1073 E:1076 ||| IN
tissue  ||| S:1076 E:1083 ||| NN
remodeling  ||| S:1083 E:1094 ||| NN
and  ||| S:1094 E:1098 ||| CC
the  ||| S:1098 E:1102 ||| DT
characteristics  ||| S:1102 E:1118 ||| NN
of  ||| S:1118 E:1121 ||| IN
the  ||| S:1121 E:1125 ||| DT
articular  ||| S:1125 E:1135 ||| JJ
cartilage ||| S:1135 E:1144 ||| NN
.  ||| S:1144 E:1146 ||| .
Better  ||| S:1146 E:1153 ||| JJR
insights  ||| S:1153 E:1162 ||| NNS
into  ||| S:1162 E:1167 ||| IN
their  ||| S:1167 E:1173 ||| PRP$
individual  ||| S:1173 E:1184 ||| JJ
characteristics  ||| S:1184 E:1200 ||| NNS
may  ||| S:1200 E:1204 ||| MD
lead  ||| S:1204 E:1209 ||| VB
to  ||| S:1209 E:1212 ||| TO
better  ||| S:1212 E:1219 ||| RBR
therapeutic  ||| S:1219 E:1231 ||| JJ
strategies ||| S:1231 E:1241 ||| NNS
,  ||| S:1241 E:1243 ||| ,
specific  ||| S:1243 E:1252 ||| JJ
targets  ||| S:1252 E:1260 ||| NNS
and  ||| S:1260 E:1264 ||| CC
useful  ||| S:1264 E:1271 ||| JJ
biomarkers ||| S:1271 E:1281 ||| NN
.  ||| S:1281 E:1283 ||| .
